News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Transcenta Holding (06628.HK) LIV1 Antibody-Drug Conjugate Preclinical Data Demonstrate Strong Anti-tumor Activity
Transcenta Holding-B (06628.HK) announced that it presented preclinical data at the 2026 AACR Annual Meeting highlighting its internally developed LIV1 antibody-drug conjugate (ADC...
Reset
Send
The window will close in 5 seconds
Transcenta Holding (06628.HK) LIV1 Antibody-Drug Conjugate Preclinical Data Demonstrate Strong Anti-tumor Activity
Close
Recommend
1
Positive
1
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

Transcenta Holding-B (06628.HK)  +0.070 (+4.636%)   announced that it presented preclinical data at the 2026 AACR Annual Meeting highlighting its internally developed LIV1 antibody-drug conjugate (ADC). The data demonstrated strong anti-tumor activity, differentiated payload-dependent efficacy, and favorable tolerability profiles, supporting further development in LIV1-positive solid tumors.

LIV1 is a member of the zinc transporter protein family. It has limited expression in normal tissues but is highly expressed in breast cancer (93%), prostate cancer (72%), and lung cancer (10%), making it a notable cell surface target for the development of ADC therapies.

The data showed that Transcentas LIV1 ADC-2 and ADC-3 programs, as monotherapies, demonstrated strong anti-tumor activity in PDX models of ER-positive/HER2-negative breast cancer (accounting for approximately 60% of all breast cancer cases) and prostate cancer. ADC-2 and ADC-3 also exhibited excellent tolerability profiles in mice. (jl/w)(HK stocks quote is delayed for at least 15 mins.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.